Skip to Main Content
Access your saved content
This article by Eugene Jones and Christopher McKenna from Accenture highlights that new ways have to be developed to ensure that quality is being built early on in the process versus back-end testing.
This article by Eugene Jones and Christopher McKenna from Accenture posits that new ways have to be developed to ensure that quality is being built early in the process versus being addressed through back-end testing.
The supply chains of global pharmaceutical manufacturers have become increasingly complex. And while globalization has benefited manufacturers in allowing them to produce products at a more competitive price and to be closer to emerging markets, the pressure for quality is now more challenging than ever before. Pharmaceutical companies are realizing that extended manufacturing supply chains—especially the extensive use of third-party manufacturers throughout the world—also exponentially increases the risk of quality problems.
Creating the complete manufacturing process requires building quality into the design and having a comprehensive quality program. This will allow a pharmaceutical manufacturer to succeed at reaping the benefits of globalization and digital connectivity while answering the rallying cry of consumers across the board.
July 12, 2011
Skip Footer Links